VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 17, 2013) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that the Company has amended its exclusive agreement with bo pharma BV to distribute Verisante Aura™ in the Nordic countries of Sweden, Norway, Denmark, Finland and Iceland; in addition to Belgium, the Netherlands and Luxemburg ("Benelux").
"Bo pharma is committed to expanding its distribution facilities to service this region," said Thomas Braun, President & CEO of Verisante. "With this foundation and bo pharma's experience and expertise in distributing the world's top brands in dermatological and skin care devices; this provides us with an excellent opportunity to expand our partnership into this important region. Bo pharma has the resources to both distribute Aura™, and provide support, technical training and servicing in the Nordic countries."
Last year, Aura™ received the Conformite Europeenne (CE) Mark approval, which is recognized by all the 27 Member States of the EU, including Sweden, Denmark and Finland, which, along with Norway and Iceland (who, while not members of the EU, are European Economic Area signatories and accept the CE Mark), have a total population of over 25 million people, and approximately 1,000 dermatologists serving the region.
"Aura™ is a game-changing device in the field of skin cancer diagnosis," said Dr. Henk-Peter Oonk, CEO of bo pharma. "We anticipate significant demand of this new technology in Benelux and welcome the opportunity to widen this adoption into the Nordic countries, where bo pharma has rapid expansion plans."
Verisante Aura™ is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Aura™ is a non-invasive optical system that uses Raman spectroscopy to biochemically analyze the skin, providing immediate and accurate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.
About bo pharma BV
Bo pharma BV is a medical device distributor of innovative technology solutions, founded in the Netherlands in 2004. In 2007, bo pharma received a distributors award for fastest sales growth and by 2011 has become the largest independent distributor of medical devices in the Benelux region.
For more information on BO-Pharma BV, visit the Company's websites at http://www.bo-pharma.com/ and http://www.bo-esthetics.com/.
About Verisante Technology, Inc.
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. The Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale.
Verisante Aura™ was awarded Popular Science Magazine's "Best of What's New Award" for 2011, and Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. In addition, the Company was named as the year's top ranking Technology and Life Sciences Company on the TSX Venture 50.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.